Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

NCT03618056 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

1

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: AIDSVAX® B/E

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)